Compared with traditional drug R&D CROs that provide a limited range of services, Cyagen can provide researchers with a more convenient and efficient one-stop service that can effectively help control R&D costs, shorten the development cycle of new drugs, and reduce R&D risks.
Cyagen is a leading life science research model service provider who has developed various robust platforms related to gene therapy covering a variety of rare human diseases.
|
Gene Prediction and Verification Platform |
Viral Vector Design and Development |
Custom Animal Model Generation Services |
Effectiveness Evaluation |
|
|
|
|
1. Full Service Gene Therapy CRO Platform
Cyagen’s platform covers the entire gene therapy process: from the construction and development of virus vectors, virus packaging and production, creation of gene therapy disease model, to the effective evaluation of gene therapy — our gene therapy CRO platform has rigorous process standards to ensure the consistency and reliability of your research data under a uniformly controlled system.
2. Advanced Bioinformatics Platform
To maximize the impact of Cyagen’s accumulated data on biological information and gene editing, our talented team of big data, AI technology, and bioinformatics background experts is working on establishing a database for gene therapy researchers. This platform uses data sets and algorithm models in the field of gene therapy that will contribute to the risk prediction of human gene mutations and the design of corresponding mouse disease models. Additionally, the database will provide design optimization of gene therapy vector AAV virus capsid proteins., which can be conducive to categorizing and observing disease types, affected protein structure, tissue type, mutation location, and so forth.
3. Leading AI technology supports the optimization and transformation of AAV
The training of AI technology based on deep learning has led to breakthroughs in the optimization and transformation of AAV: quickly and accurately predicts the sequence of AAV capsid protein, obtains the most expected new AAV serotype, and improves upon the effectiveness of AAV vectors and targeted tissue specificity in gene therapy applications. Cyagen’s synthetic biology platform can provide optimized AAV vectors for the development of gene therapy models alongside the necessary downstream validation testing.
4. Risk prediction of pathogenic mutation site
By combining AI technology with our accumulated biological information and gene editing data, Cyagen has established a prediction model for the pathogenicity of gene mutation sites. We can use this prediction model to obtain the mutation sites that are most likely to lead to disease phenotype and construct relevant cell or animal models for verification, which makes a great contribution to the development of gene therapy research.
5. In vivo and in vitro models: one-stop service
The research groups of Dr. Bin Zhou and the team of Dr. Hefeng Huang co-published an article titled "In Vivo AAV-CRISPR/Cas-mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia" in the journal Circulation. In this study, researchers find that adeno-associated virus (AAV) delivers CRISPR/Cas to achieve low-density lipoprotein receptor (LDLR) gene correction that can partially rescue LDLR expression and effectively ameliorate atherosclerosis phenotypes in Ldlr mutant mice generated by Cyagen. This finding provides a potential therapeutic method for the treatment of familial hypercholesterolemia (FH).
Inquiries and Quote Requests
Request a quote now. Alternatively, you can always email service-apac@cyagen.com or call 86 20-31601779 to inquire about our services or obtain a quote for your project.
Related Posts:
>> Viral Vector Design and Development